These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 28794627)

  • 1. In situ imaging of quantum dot-AZD4547 conjugates for tracking the dynamic behavior of fibroblast growth factor receptor 3.
    Hwang G; Kim H; Yoon H; Song C; Lim DK; Sim T; Lee J
    Int J Nanomedicine; 2017; 12():5345-5357. PubMed ID: 28794627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance.
    Chell V; Balmanno K; Little AS; Wilson M; Andrews S; Blockley L; Hampson M; Gavine PR; Cook SJ
    Oncogene; 2013 Jun; 32(25):3059-70. PubMed ID: 22869148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Functional Genetic Screen Identifies the Phosphoinositide 3-kinase Pathway as a Determinant of Resistance to Fibroblast Growth Factor Receptor Inhibitors in FGFR Mutant Urothelial Cell Carcinoma.
    Wang L; Šuštić T; Leite de Oliveira R; Lieftink C; Halonen P; van de Ven M; Beijersbergen RL; van den Heuvel MM; Bernards R; van der Heijden MS
    Eur Urol; 2017 Jun; 71(6):858-862. PubMed ID: 28108151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family.
    Gavine PR; Mooney L; Kilgour E; Thomas AP; Al-Kadhimi K; Beck S; Rooney C; Coleman T; Baker D; Mellor MJ; Brooks AN; Klinowska T
    Cancer Res; 2012 Apr; 72(8):2045-56. PubMed ID: 22369928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Theoretical studies on FGFR isoform selectivity of FGFR1/FGFR4 inhibitors by molecular dynamics simulations and free energy calculations.
    Fu W; Chen L; Wang Z; Kang Y; Wu C; Xia Q; Liu Z; Zhou J; Liang G; Cai Y
    Phys Chem Chem Phys; 2017 Feb; 19(5):3649-3659. PubMed ID: 28094372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibroblast Growth Factor Receptors as Targets for Radiosensitization in Head and Neck Squamous Cell Carcinomas.
    Fisher MM; SenthilKumar G; Hu R; Goldstein S; Ong IM; Miller MC; Brennan SR; Kaushik S; Abel L; Nickel KP; Iyer G; Harari PM; Kimple RJ; Baschnagel AM
    Int J Radiat Oncol Biol Phys; 2020 Jul; 107(4):793-803. PubMed ID: 32298810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of fibroblast growth factor receptor with AZD4547 mitigates juvenile nasopharyngeal angiofibroma.
    Le T; New J; Jones JW; Usman S; Yalamanchali S; Tawfik O; Hoover L; Bruegger DE; Thomas SM
    Int Forum Allergy Rhinol; 2017 Oct; 7(10):973-979. PubMed ID: 28707818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms of Efficacy of the FGFR1-3 Inhibitor AZD4547 in Pediatric Solid Tumor Models.
    Phanhthilath N; Hakim S; Su C; Liu A; Subramonian D; Lesperance J; Zage PE
    Invest New Drugs; 2020 Dec; 38(6):1677-1686. PubMed ID: 32436058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of FGFR inhibitors TKI258, BGJ398 and AZD4547 on breast cancer cells in 2D, 3D and tissue explant cultures.
    Kähkönen TE; Toriseva M; Petruk N; Virta AR; Maher A; Eigéliené N; Kaivola J; Boström P; Koskivuo I; Nees M; Tuomela JM; Ivaska KK; Härkönen PL
    Cell Oncol (Dordr); 2021 Feb; 44(1):205-218. PubMed ID: 33119860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FGFR inhibitor, AZD4547, impedes the stemness of mammary epithelial cells in the premalignant tissues of MMTV-ErbB2 transgenic mice.
    Zhao Q; Parris AB; Howard EW; Zhao M; Ma Z; Guo Z; Xing Y; Yang X
    Sci Rep; 2017 Sep; 7(1):11306. PubMed ID: 28900173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction between the estrogen receptor and fibroblast growth factor receptor pathways in non-small cell lung cancer.
    Siegfried JM; Farooqui M; Rothenberger NJ; Dacic S; Stabile LP
    Oncotarget; 2017 Apr; 8(15):24063-24076. PubMed ID: 28445992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insight into resistance mechanisms of AZD4547 and E3810 to FGFR1 gatekeeper mutation via theoretical study.
    Liang D; Chen Q; Guo Y; Zhang T; Guo W
    Drug Des Devel Ther; 2017; 11():451-461. PubMed ID: 28255231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The 1.65 Å resolution structure of the complex of AZD4547 with the kinase domain of FGFR1 displays exquisite molecular recognition.
    Yosaatmadja Y; Patterson AV; Smaill JB; Squire CJ
    Acta Crystallogr D Biol Crystallogr; 2015 Mar; 71(Pt 3):525-33. PubMed ID: 25760602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Landscape of activating cancer mutations in FGFR kinases and their differential responses to inhibitors in clinical use.
    Patani H; Bunney TD; Thiyagarajan N; Norman RA; Ogg D; Breed J; Ashford P; Potterton A; Edwards M; Williams SV; Thomson GS; Pang CS; Knowles MA; Breeze AL; Orengo C; Phillips C; Katan M
    Oncotarget; 2016 Apr; 7(17):24252-68. PubMed ID: 26992226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AZD4547 targets the FGFR/Akt/SOX2 axis to overcome paclitaxel resistance in head and neck cancer.
    Aytatli A; Barlak N; Sanli F; Caglar HO; Gundogdu B; Tatar A; Ittmann M; Karatas OF
    Cell Oncol (Dordr); 2022 Feb; 45(1):41-56. PubMed ID: 34837170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transcriptomics and Transposon Mutagenesis Identify Multiple Mechanisms of Resistance to the FGFR Inhibitor AZD4547.
    Kas SM; de Ruiter JR; Schipper K; Schut E; Bombardelli L; Wientjens E; Drenth AP; de Korte-Grimmerink R; Mahakena S; Phillips C; Smith PD; Klarenbeek S; van de Wetering K; Berns A; Wessels LFA; Jonkers J
    Cancer Res; 2018 Oct; 78(19):5668-5679. PubMed ID: 30115694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibroblast growth factor receptor promotes progression of cutaneous squamous cell carcinoma.
    Khandelwal AR; Kent B; Hillary S; Alam MM; Ma X; Gu X; DiGiovanni J; Nathan CO
    Mol Carcinog; 2019 Oct; 58(10):1715-1725. PubMed ID: 31254372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Photopreventive Effect and Mechanism of AZD4547 and Curcumin C3 Complex on UVB-Induced Epidermal Hyperplasia.
    Khandelwal AR; Rong X; Moore-Medlin T; Ekshyyan O; Abreo F; Gu X; Nathan CA
    Cancer Prev Res (Phila); 2016 Apr; 9(4):296-304. PubMed ID: 26862088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic suppression of a disintegrin acurhagin-C in combination with AZD4547 and reparixin on terminating development for human osteosarcoma MG-63 cell.
    Shih CH; Chiang TB; Wang WJ
    Biochem Biophys Res Commun; 2017 Oct; 492(3):513-519. PubMed ID: 28823917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multikinase activity of fibroblast growth factor receptor (FGFR) inhibitors SU5402, PD173074, AZD1480, AZD4547 and BGJ398 compromises the use of small chemicals targeting FGFR catalytic activity for therapy of short-stature syndromes.
    Gudernova I; Vesela I; Balek L; Buchtova M; Dosedelova H; Kunova M; Pivnicka J; Jelinkova I; Roubalova L; Kozubik A; Krejci P
    Hum Mol Genet; 2016 Jan; 25(1):9-23. PubMed ID: 26494904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.